Microscopy & Microtechniques

  • Collaboration to Deliver a Complete Single-Cell and CRISPR Genetic Manipulation Solution in the Americas Announced

Collaboration to Deliver a Complete Single-Cell and CRISPR Genetic Manipulation Solution in the Americas Announced

Jul 24 2020 Read 3028 Times

Olympus, a leading manufacturer of high-end research microscopes, and Cytosurge, a precision manufacturer of cell manipulation technologies, have entered a co-marketing agreement to become a complete system provider to the scientific community’s growing need for next-generation single-cell and CRISPR genetic manipulation solutions.

The demand continues to rise as researchers see their potential to study diseases, find medical treatments and benefit human health. Cytosurge provides a powerful genetic manipulation solution with the FluidFM® BOT BIO Series, a highly automated system built on the Olympus IX83 inverted microscope with Olympus’ renowned optics. In addition to CRISPR genome editing, the system’s core functionalities - intracellular- and nuclear- injection and extraction, pick-and-place at the microscale, and precise dispensing of liquids - enables a broad range of applications, including single-cell drug assays, monoclonal cell line development and nanoprinting of custom patterns.

“We are very excited to formalise a partnership with Cytosurge, as we have worked with them for many years,” said Lee Wagstaff, Vice President of Life Science Sales and Marketing at Olympus Corporation of the Americas. “With the FluidFM BOT BIO Series, we see tremendous potential for continued collaboration to blend our optical technologies with their high-precision cell manipulation technologies.” 

Wagstaff continued: “The increasing interest in CRISPR genetic manipulation is just one of the many important trends that shows the importance of using this technology to help understand the biological mechanisms of disease and improve the health and well-being of society. We look forward to increasing our joint activities, which will aid researchers in academia, the pharmaceutical industry and precision medicine field.”

Cytosurge CEO Pascal Behr, commented, “The USA was the last missing key market in Cytosurge’s strategic development plan to cover the globe. Our new partnership with Olympus Corporation of the Americas epitomises the objectives and values of our company, embodying a very high level of understanding and mutual trust. Everything is ready for a rapid and effective market launch to make our remarkable FluidFM technology available on the American continent. With this, we are empowering researchers in both academia and the private sector to go beyond current technological barriers and help them bring new, much-needed therapies and medications to the market faster.”

Reader comments

Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.

Post a Comment

Digital Edition

LabAsia Buyers Guide 2020

October 2020

In This Edition Articles - Ambient Ionisation MS and GC-MS Analysis and Identification of Aroma Compounds in Agave Based Alcoholic Beverages - How a Chromatographic Method is More Than a Sep...

View all digital editions



Oct 27 2020 Kiev, Ukraine


Oct 27 2020 Moscow, Russia

Thailand Lab 2020 - NEW DATES

Oct 28 2020 Bitec Hall, Bangkok, Thailand

Expomed Eurasia - NEW DATES

Nov 05 2020 Istanbul, Turkey

Pharma Asia - NEW DATES

Nov 10 2020 Karachi, Pakistan

View all events